Pembrolizumab Plus Lenvatinib Breakthroughs: KEYNOTE-581 Trial Kidney 12 Mins Read0 Pembrolizumab plus Lenvatinib, individually known for their robust anti-cancer mechanisms, when combined, show significant promise in treating advanced renal cell…
AVEO Oncology ASCO 2023 Updates Martin Birkhofer, MD Kidney 2 Mins Read1 FOTIVDA is Aveo’s marketed product for treating advanced renal cell carcinoma, primarily used as a later line agent in the…
Kidney Cancer Breakthrough: KEYTRUDA Plus LENVIMA Results for Advanced RCC Kidney 3 Mins Read1 Corina Dutcus, MD from Eisai Inc provided a summary of the findings from a clinical trial evaluating the combination of…
